GlassScriptPhysician profile
Chelsea Eason
NPI 1083239677
$3,081.25
in general payments reported to CMS, 2019-2025
18 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $490 · 2023: $988 · 2024: $322 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,141.83 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $521.50 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $399.36 | 2021-2025 | Tremfya |
| Janssen Biotech, INC. | $269.80 | 2024-2025 | Tremfya, Stelara |
| Galderma Laboratories, L.P. | $258.08 | 2023 | Oracea, Epsolay |
| Abbvie INC. | $228.22 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $219.96 | 2024-2025 | |
| Incyte Corporation | $168.57 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $163.39 | 2022-2025 | Dupixent |
| Ucb, INC. | $154.37 | 2023 | Cimzia |
| Sun Pharmaceutical Industries INC. | $149.14 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.54 | 2023 | Spevigo |
| Krystal Biotech INC | $119.70 | 2023 | Vyjuvek |
| Leo Pharma INC. | $99.02 | 2025 | Adbry |
| Revance Therapeutics, INC. | $69.68 | 2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $67.10 | 2023 | Sotyktu |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $25.84 | 2025 | Zoryve |
| Lilly USA, LLC | $23.13 | 2025 | Taltz, Ebglyss |
| Verrica Pharmaceuticals INC. | $21.85 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Eason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.